Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05882045 · ClinicalTrials.gov registry record · Phase 3
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
A Phase 3 study of Obesity and Cardiovascular Diseases, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 1,800
- Enrollment target
- 20
- Study locations
NCT05882045: Active Phase 3 study of Obesity and Cardiovascular Diseases, sponsored by Eli Lilly and Company.
NCT05882045 is a Phase 3 study of Obesity and Cardiovascular Diseases that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 1,800 participants, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (120% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05882045, a Phase 3 study of Obesity and Cardiovascular Diseases, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,800 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Retatrutide
Study Locations (20)
California
- Valley Clinical Trials, Inc. - Covina
- Neuro-Pain Medical Center - Fresno
- Valley Research - Fresno
- Collaborative Neuroscience Research, LLC - Los Alamitos
- Velocity Clinical Research, Westlake - Los Angeles
- Valley Clinical Trials, Inc. - Northridge
- Velocity Clinical Research, Panorama City - Van Nuys
Florida
- Indago Research & Health Center, Inc - Hialeah
- Clinical Neuroscience Solutions, Inc. dba CNS Healthcare - Jacksonville
- Clinical Neuroscience Solutions, Inc. - Orlando
- Charter Research - Winter Park - Orlando
- Progressive Medical Research - Port Orange
Illinois
- Northwestern University - Chicago
- Great Lakes Clinical Trials - Gurnee - Gurnee
- Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative - Springfield
Idaho
- Elite Clinical Trials - Blackfoot
- Humphreys Diabetes Center - Boise
Arizona
- Central Phoenix Medical Clinic - Phoenix
Connecticut
- Chase Medical Research, LLC - Waterbury
Hawaii
- Pacific Diabetes & Endocrine Center - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2023-05-30 |
| Est. Completion | 2026-05 |
| Phase | Phase 3 |
What the registry record for NCT05882045 still lists
NCT05882045 is an interventional study that assigns participants to a tested intervention. Its 1,800 participants enrollment target places it among the larger protocols in the corpus, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (120% higher).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05882045 names 20 study sites across 7 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05882045 about?
NCT05882045 is a clinical study titled "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease". The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
What is the current status of trial NCT05882045?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,800 participants. The study started on 2023-05-30. Estimated completion is 2026-05.
What conditions does trial NCT05882045 study?
This clinical trial studies the following conditions: Obesity, Cardiovascular Diseases.
What interventions are being tested in trial NCT05882045?
The interventions under investigation include: Placebo (DRUG), Retatrutide (DRUG).
Who is sponsoring clinical trial NCT05882045?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05882045 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05882045's enrollment target sits among peer trials
1,800 49th of 1053 higher than 1,004 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI